SPCX gained +5.89% during regular trading, rising to $148.25 from Friday's $140.00 close. The advance extends a rebound that carried shares back above the $135 IPO price after the August 6 lockup expiry failed to trigger heavy selling.
NWBO is the ticker for Northwest Biotherapeutics, Inc., a clinical-stage biotechnology company focused on personalized cancer immunotherapy. The company's lead candidate, DCVax-L, targets glioblastoma, an aggressive form of brain cancer, and has completed a Phase III clinical trial.
SPXS fell approximately 11.6% over the trailing 30 days, moving from a closing price of $26.98 to a latest price near $23.86, as the S&P 500 advanced. Over the trailing three-month period, the fund declined roughly 13.9% , extending a downward trend driven by broad large-cap equity strength.
PURR is up +5.99% to $7.08 in regular trading versus the previous session close of $6.68. The gain is occurring during market hours after shares gapped higher in the premarket.
Selected price target: $40, roughly 22% above the most recent close and just above the highest published analyst target near $39. Strongest bullish factors: accelerating revenue growth, a major second-quarter earnings beat, raised full-year guidance, improving profitability, and a cash-rich balance sheet.
United States Oil Fund, LP (USO) is a commodity-pool exchange-traded product, rather than a conventional equity exchange-traded fund (ETF), that seeks to track daily percentage changes in West Texas Intermediate (WTI) light, sweet crude oil through near-month New York Mercantile Exchange (NYMEX) futures. The fund's concentrated exposure to crude oil futures makes WTI price direction, the shape of the futures curve, and collateral yields the dominant drivers of ETF performance.
STUB is trading down -10.89% at $7.20 during Monday's regular session, extending its post-earnings slide. Pressure follows reports of a proposed class action over ticketing failures and delayed refunds.
Selected price target: $200 per share, roughly 15% above Reddit's recent trading range near $173–$178. Strongest bullish factors: better-than-expected second-quarter revenue and earnings, 91% gross margin, 50% average revenue per user growth, and S&P 500 inclusion.
Innovative Aerosystems, Inc. (ISSC) reported strong fiscal Q3 2026 results with revenue growth and margin expansion, while StandardAero, Inc. (SARO) delivered steady but more modest revenue increases in recent quarters. ISSC stock has shown notable upward momentum in recent weeks amid new orders and acquisitions, contrasting with SARO's more stable performance relative to broader market indices.
Upcoming earnings releases, including the next scheduled report in December 2026, could provide updates on revenue growth from commercial and military avionics demand. Strategic positioning in retrofit and original equipment manufacturer (OEM) markets for flight control systems offers medium-term expansion potential amid recovering aviation sectors.
Selected stock price target: $10 per share, approximately 50% above the recent price near $6.68. Strongest bullish factors: analyst targets clustered near or above $10, a proven ability to trade above $10 in June 2026, and treasury value tied directly to the HYPE token.
ISSC climbed 34.1% over the last 30 days, from an $18.46 close on July 17, 2026, to $24.76 intraday on August 17, 2026. The move accelerated after fiscal third-quarter results beat estimates, with adjusted EPS of $0.33 versus a $0.24 consensus.
Enovix is trading down -18.45% to $3.58 in Monday's regular session, versus Friday's close of $4.39. The primary catalyst: CEO Raj Talluri resigned effective Aug. 13; CFO Ryan Benton was named interim CEO and Chairman T.J. Rodgers became executive chairman.
NNNN rallied +39.10% to $12.38 in early regular trading Monday, extending a premarket gain of roughly +18%. The advance occurred during normal market hours, with NNNN opening near $12.00 and touching a $12.64 session high.
FTK is trading down -14.01% to $30.81 during Monday’s regular session as of 9:41 a.m. ET, versus Friday’s close of $35.83. The move occurred in early regular trading after a gap lower at the open; the stock opened at $31.44 and has traded between $30.19 and $32.01.
OmniAb shares are up +20.71% to $4.08 in Monday regular trading after gapping higher in the premarket. The primary catalyst is a global collaboration and license agreement with Eli Lilly for a new ion channel discovery program, including an upfront payment, up to $370 million in milestone payments, and tiered royalties.
EYPT is down -69.49% to $4.50 as of 9:36 a.m. ET Monday, versus Friday's regular-session close of $14.75, during regular trading after a premarket halt. The primary catalyst is topline Phase 3 LUGANO data showing Duravyu missed its primary endpoint for change in best corrected visual acuity versus aflibercept in wet AMD.
WRAP is trading down -13.83% at $1.62 in Monday's regular session, extending a premarket slide from Friday's $1.88 close. The primary catalyst is a $12.0 million registered direct offering priced at $1.40 per share, a steep discount to Friday's close, fueling dilution concerns.
Upcoming Phase 2 data readouts and potential regulatory advancements for lead candidate ABCL635 represent major near-term catalysts in the vasomotor symptoms market. Strategic positioning through a proprietary AI-driven antibody discovery platform provides competitive differentiation in addressing complex targets and novel modalities.
AbCellera Biologics shares gained approximately 76% over the 30-day period through the latest available close, rising from $6.47 on July 17, 2026, to $11.38 on August 14, 2026. The decisive catalyst was positive Phase 2 data for ABCL635, an investigational antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause.